Copyright Reports & Markets. All rights reserved.

Global Acute Intermittent Porphyria Therapeutics Market Insights, Forecast to 2025

Request for Sample of this report
Buy now

Table of Contents

    1 Study Coverage

    • 1.1 Acute Intermittent Porphyria Therapeutics Product
    • 1.2 Market Segments
    • 1.3 Key Manufacturers Covered
    • 1.4 Market by Type
      • 1.4.1 Global Acute Intermittent Porphyria Therapeutics Market Size Growth Rate by Product
      • 1.4.2 350mg
      • 1.4.3 313mg
    • 1.5 Market by End User
      • 1.5.1 Global Acute Intermittent Porphyria Therapeutics Market Size Growth Rate by End User
      • 1.5.2 Hospital
      • 1.5.3 Pharmacy
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Executive Summary

    • 2.1 Global Acute Intermittent Porphyria Therapeutics Market Size
      • 2.1.1 Global Acute Intermittent Porphyria Therapeutics Revenue 2014-2025
      • 2.1.2 Global Acute Intermittent Porphyria Therapeutics Sales 2014-2025
    • 2.2 Acute Intermittent Porphyria Therapeutics Growth Rate by Regions
      • 2.2.1 Global Acute Intermittent Porphyria Therapeutics Sales by Regions
      • 2.2.2 Global Acute Intermittent Porphyria Therapeutics Revenue by Regions

    3 Breakdown Data by Manufacturers

    • 3.1 Acute Intermittent Porphyria Therapeutics Sales by Manufacturers
      • 3.1.1 Acute Intermittent Porphyria Therapeutics Sales by Manufacturers
      • 3.1.2 Acute Intermittent Porphyria Therapeutics Sales Market Share by Manufacturers
      • 3.1.3 Global Acute Intermittent Porphyria Therapeutics Market Concentration Ratio (CR5 and HHI)
    • 3.2 Acute Intermittent Porphyria Therapeutics Revenue by Manufacturers
      • 3.2.1 Acute Intermittent Porphyria Therapeutics Revenue by Manufacturers (2014-2019)
      • 3.2.2 Acute Intermittent Porphyria Therapeutics Revenue Share by Manufacturers (2014-2019)
    • 3.3 Acute Intermittent Porphyria Therapeutics Price by Manufacturers
    • 3.4 Acute Intermittent Porphyria Therapeutics Manufacturing Base Distribution, Product Types
      • 3.4.1 Acute Intermittent Porphyria Therapeutics Manufacturers Manufacturing Base Distribution, Headquarters
      • 3.4.2 Manufacturers Acute Intermittent Porphyria Therapeutics Product Type
      • 3.4.3 Date of International Manufacturers Enter into Acute Intermittent Porphyria Therapeutics Market
    • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Product

    • 4.1 Global Acute Intermittent Porphyria Therapeutics Sales by Product
    • 4.2 Global Acute Intermittent Porphyria Therapeutics Revenue by Product
    • 4.3 Acute Intermittent Porphyria Therapeutics Price by Product

    5 Breakdown Data by End User

    • 5.1 Overview
    • 5.2 Global Acute Intermittent Porphyria Therapeutics Breakdown Data by End User

    6 North America

    • 6.1 North America Acute Intermittent Porphyria Therapeutics by Countries
      • 6.1.1 North America Acute Intermittent Porphyria Therapeutics Sales by Countries
      • 6.1.2 North America Acute Intermittent Porphyria Therapeutics Revenue by Countries
      • 6.1.3 United States
      • 6.1.4 Canada
      • 6.1.5 Mexico
    • 6.2 North America Acute Intermittent Porphyria Therapeutics by Product
    • 6.3 North America Acute Intermittent Porphyria Therapeutics by End User

    7 Europe

    • 7.1 Europe Acute Intermittent Porphyria Therapeutics by Countries
      • 7.1.1 Europe Acute Intermittent Porphyria Therapeutics Sales by Countries
      • 7.1.2 Europe Acute Intermittent Porphyria Therapeutics Revenue by Countries
      • 7.1.3 Germany
      • 7.1.4 France
      • 7.1.5 UK
      • 7.1.6 Italy
      • 7.1.7 Russia
    • 7.2 Europe Acute Intermittent Porphyria Therapeutics by Product
    • 7.3 Europe Acute Intermittent Porphyria Therapeutics by End User

    8 Asia Pacific

    • 8.1 Asia Pacific Acute Intermittent Porphyria Therapeutics by Countries
      • 8.1.1 Asia Pacific Acute Intermittent Porphyria Therapeutics Sales by Countries
      • 8.1.2 Asia Pacific Acute Intermittent Porphyria Therapeutics Revenue by Countries
      • 8.1.3 China
      • 8.1.4 Japan
      • 8.1.5 Korea
      • 8.1.6 India
      • 8.1.7 Australia
      • 8.1.8 Indonesia
      • 8.1.9 Malaysia
      • 8.1.10 Philippines
      • 8.1.11 Thailand
      • 8.1.12 Vietnam
      • 8.1.13 Singapore
    • 8.2 Asia Pacific Acute Intermittent Porphyria Therapeutics by Product
    • 8.3 Asia Pacific Acute Intermittent Porphyria Therapeutics by End User

    9 Central & South America

    • 9.1 Central & South America Acute Intermittent Porphyria Therapeutics by Countries
      • 9.1.1 Central & South America Acute Intermittent Porphyria Therapeutics Sales by Countries
      • 9.1.2 Central & South America Acute Intermittent Porphyria Therapeutics Revenue by Countries
      • 9.1.3 Brazil
    • 9.2 Central & South America Acute Intermittent Porphyria Therapeutics by Product
    • 9.3 Central & South America Acute Intermittent Porphyria Therapeutics by End User

    10 Middle East and Africa

    • 10.1 Middle East and Africa Acute Intermittent Porphyria Therapeutics by Countries
      • 10.1.1 Middle East and Africa Acute Intermittent Porphyria Therapeutics Sales by Countries
      • 10.1.2 Middle East and Africa Acute Intermittent Porphyria Therapeutics Revenue by Countries
      • 10.1.3 GCC Countries
      • 10.1.4 Turkey
      • 10.1.5 Egypt
      • 10.1.6 South Africa
    • 10.2 Middle East and Africa Acute Intermittent Porphyria Therapeutics by Product
    • 10.3 Middle East and Africa Acute Intermittent Porphyria Therapeutics by End User

    11 Company Profiles

    • 11.1 Abbott
      • 11.1.1 Abbott Company Details
      • 11.1.2 Company Business Overview
      • 11.1.3 Abbott Acute Intermittent Porphyria Therapeutics Sales, Revenue and Gross Margin (2014-2019)
      • 11.1.4 Abbott Acute Intermittent Porphyria Therapeutics Products Offered
      • 11.1.5 Abbott Recent Development

    12 Future Forecast

    • 12.1 Acute Intermittent Porphyria Therapeutics Market Forecast by Regions
      • 12.1.1 Global Acute Intermittent Porphyria Therapeutics Sales Forecast by Regions 2019-2025
      • 12.1.2 Global Acute Intermittent Porphyria Therapeutics Revenue Forecast by Regions 2019-2025
    • 12.2 Acute Intermittent Porphyria Therapeutics Market Forecast by Product
      • 12.2.1 Global Acute Intermittent Porphyria Therapeutics Sales Forecast by Product 2019-2025
      • 12.2.2 Global Acute Intermittent Porphyria Therapeutics Revenue Forecast by Product 2019-2025
    • 12.3 Acute Intermittent Porphyria Therapeutics Market Forecast by End User
    • 12.4 North America Acute Intermittent Porphyria Therapeutics Forecast
    • 12.5 Europe Acute Intermittent Porphyria Therapeutics Forecast
    • 12.6 Asia Pacific Acute Intermittent Porphyria Therapeutics Forecast
    • 12.7 Central & South America Acute Intermittent Porphyria Therapeutics Forecast
    • 12.8 Middle East and Africa Acute Intermittent Porphyria Therapeutics Forecast

    13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

    • 13.1 Market Opportunities and Drivers
    • 13.2 Market Challenges
    • 13.3 Market Risks/Restraints
    • 13.4 Macroscopic Indicators

    14 Value Chain and Sales Channels Analysis

    • 14.1 Value Chain Analysis
    • 14.2 Acute Intermittent Porphyria Therapeutics Customers
    • 14.3 Sales Channels Analysis
      • 14.3.1 Sales Channels
      • 14.3.2 Distributors

    15 Research Findings and Conclusion

      16 Appendix

      • 16.1 Research Methodology
        • 16.1.1 Methodology/Research Approach
        • 16.1.2 Data Source
      • 16.2 Author Details

      Acute intermittent porphyria (AIP), also called Swedish porphyria, pyrroloporphyria, intermittent acute porphyria) is a rare autosomal dominant metabolic disorder affecting the production of heme resulting from a deficiency of the porphobilinogen deaminase. It is the most common of the acute porphyrias.
      The global Acute Intermittent Porphyria Therapeutics market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Acute Intermittent Porphyria Therapeutics market based on company, product type, end user and key regions.

      This report studies the global market size of Acute Intermittent Porphyria Therapeutics in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Acute Intermittent Porphyria Therapeutics in these regions.
      This research report categorizes the global Acute Intermittent Porphyria Therapeutics market by top players/brands, region, type and end user. This report also studies the global Acute Intermittent Porphyria Therapeutics market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

      The following manufacturers are covered in this report, with sales, revenue, market share for each company:
      Abbott

      Market size by Product
      350mg
      313mg
      Market size by End User
      Hospital
      Pharmacy

      Market size by Region
      North America
      United States
      Canada
      Mexico
      Asia-Pacific
      China
      India
      Japan
      South Korea
      Australia
      Indonesia
      Singapore
      Malaysia
      Philippines
      Thailand
      Vietnam
      Europe
      Germany
      France
      UK
      Italy
      Spain
      Russia
      Central & South America
      Brazil
      Rest of Central & South America
      Middle East & Africa
      GCC Countries
      Turkey
      Egypt
      South Africa

      The study objectives of this report are:
      To study and analyze the global Acute Intermittent Porphyria Therapeutics market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
      To understand the structure of Acute Intermittent Porphyria Therapeutics market by identifying its various subsegments.
      To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
      Focuses on the key global Acute Intermittent Porphyria Therapeutics companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
      To project the value and sales volume of Acute Intermittent Porphyria Therapeutics submarkets, with respect to key regions.
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

      In this study, the years considered to estimate the market size of Acute Intermittent Porphyria Therapeutics are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Acute Intermittent Porphyria Therapeutics market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now